Stock

Novartis immuno-oncology drug candidate fails in pores and skin most cancers research

© Reuters. The logo of the Swiss pharmaceutical manufacturer Novartis is displayed at the headquarters of the French company in Rueil-Malmaison

ZURICH (Reuters) – The Swiss drug manufacturer Novartis said on Saturday that its drug against spartalizumab mixed with the approved drugs Tafinlar and Mekinist had failed in immuno-oncology in a late-stage study against a type of advanced skin cancer.

The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive skin melanoma compared to Tafinlar + Mekinist alone, Novartis said.

Despite the failure, Novartis continues to develop spartalizumab, a so-called checkpoint inhibitor, which is supposed to slow the immune system in the fight against cancer against other types of tumors, according to the Basel-based company.

Novartis was late in developing such immuno-oncology drugs for its portfolio, an area now dominated by lucrative drugs like Merck's Keytruda, Bristol-Myers Squibb (NYSE 🙂 Opdivo and, to a lesser extent, Roches Tecentriq.

Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and Forex prices are not provided by exchanges, but by market makers. As a result, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading loss you may incur as a result of using this information.

Fusion Media or any person involved with Fusion Media assumes no liability for any loss or damage caused by reliance on the information contained on this website, such as data, offers, charts and buy / sell signals. Please be fully informed about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.

Related Articles